Clinical Trial

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This phase IV trial studies how well Gardasil 9 vaccine works in preventing human papillomavirus (HPV) infection in patients with hematologic malignancies who are undergoing donor stem cell transplant. Vaccines, such as Gardasil 9, may help the body build an effective immune response to kill cancer cells.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07-31 -> 2026-09-30 2026-07-17
minor Completion pushed: 2026-07-31 -> 2026-09-30 2026-07-17
Trial Details
NCT Number NCT03023631
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Enrollment 48 participants
Start Date 2017-04-23
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-16